Navigation Links
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/5/2008

Interim Phase 1 Data Presented at International Conference on Malignant

Lymphomas Shows Dose Dependent Single Agent Activity

BETHESDA, Md., June 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland. The new data(1) with the CD19-specific BiTE antibody show that all seven patients in the highest dose cohort tested so far (0.06 mg/m2/day) achieved complete or partial responses.

In the study, relapsed, incurable non-Hodgkin's lymphoma (NHL) patients who previously failed a median of three (and up to 12) conventional therapies were treated with increasing doses of blinatumomab (MT103/MEDI-538) for four to eight weeks. Dose-dependent clinical activity was observed. At the recently completed cohort of 0.06 mg/m2 per day, seven out of seven patients showed either complete or partial responses. Remissions in this and the previous dose cohort continue in all patients, with the longest remission ongoing for more than one year. Most frequent side effects observed so far were lymphopenia, pyrexia, and leukopenia. Less common adverse events included transient neutropenia and thrombocytopenia, transient increase of liver enzymes, and central nervous system events, all of which were fully reversible.

"The high response rate and apparently durable remissions in this heavily pre-treated patient population support blinatumomab as a single agent therapy with the potential for accelerated development," said Micromet's Senior Vice President and Chief Medical Officer, Dr. Carsten Reinhardt.

"ICML brings together thousands of the world's leading specialists and researchers to present the latest adva
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
2. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
3. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
5. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
6. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
7. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014  The law firm McElroy, Deutsch, ... it will serve as host for "Show Me ... Risks of Healthcare Reform," a one-day conference scheduled ... systems, reimbursement, compliance and enforcement in a marketplace ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
(Date:9/17/2014)... LEIPZIG, Germany , Sept. 17, ... has entered into an exclusive technology development partnership ... imaging agents to image CD4+ positive immune T ... ImaginAb,s capability to precisely diagnose and determine therapeutic ... areas. The ability to image CD4+ T-cells will ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 US ... to implement GS1 Standards to support the 2013 ... patient safety and security in the pharmaceutical supply ... Standards to U.S. Pharmaceutical Supply Chain Business Processes ... , was developed in collaboration with GS1 ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
... TEL-AVIV, Israel , March 15, 2010 Cheetah Medical, a,worldwide leader in noninvasive hemodynamic and cardiac output ... and also included Robert,Bosch Venture Capital (RBVC), MVM Life Science Partners (MVM) and existing,investors. , ... ... ...
... With heart disease continuing to be the No. 1 cause of death in the U.S., Atherotech Inc. has ... company is expanding its disease management services with the goal of helping physicians reduce death and disability from heart disease. ... ... , ...
Cached Medicine Technology:Cheetah Medical Closes $20 Million Series B Financing 2Cheetah Medical Closes $20 Million Series B Financing 3Cheetah Medical Closes $20 Million Series B Financing 4Cheetah Medical Closes $20 Million Series B Financing 5Cheetah Medical Closes $20 Million Series B Financing 6Atherotech Recruits Top Experts in Fight Against Heart Disease 2Atherotech Recruits Top Experts in Fight Against Heart Disease 3Atherotech Recruits Top Experts in Fight Against Heart Disease 4Atherotech Recruits Top Experts in Fight Against Heart Disease 5Atherotech Recruits Top Experts in Fight Against Heart Disease 6
(Date:9/18/2014)... September 18, 2014 MD Complete ... results without a prescription, announced today that SHAPE Magazine ... the “Best Peel” in its annual Beauty Awards. ... most effective beauty products as tested by SHAPE’s expert ... real, noticeable results. Among the thousands of beauty products ...
(Date:9/18/2014)... discount dental plans website allows consumers to search ... savings in their area prior to joining the plan. Consumers ... use the plan same day. , With so many different ... be difficult. With most dental plan websites it is very ... a particular zip code before joining the plan. , That ...
(Date:9/18/2014)... 2014 With the development of ... of adjusting human body physiology, preventing diseases, promoting ... with a variety of specific populations. In 2013, ... reached RMB187.4 billion, up 12.0% year on year, ... View Full Report at http://www.marketresearchreports.biz/analysis/223449 , ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... independent freestanding emergency rooms in the United States, named ... its new Missouri City-Lakes facility. , “We are ... as facility medical director of our new Missouri City-Lakes ... of First Choice Emergency Room. , Dr. Harrison ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader ... big promotion for its maternity wedding outfits. Now, all ... discounted maternity wedding dresses on its website. ... global consumers. The company’s development manager believes the cheap ... delighted. The current special offer will last until September ...
Breaking Medicine News(10 mins):Health News:MD Complete Wins Shape Beauty Award for Best Peel 2Health News:Discount Dental Plans Allow Consumers to Search Thousands of Local Dentists, Compare Savings and Discounts, and Download a Printable Membership Card 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2
... Reporter , THURSDAY, Jan. 5 (HealthDay News) -- Pediatric ... to lower the threshold for toxic lead exposure in ... and house paint, can permanently damage developing brains. ... Poisoning Prevention voted to recommend that the federal government ...
... of patients with mild-to-moderate asthma have persistently non-eosinophilic ... anti-inflammatory treatments, according to a new study. ... enrolled in nine clinical trials conducted by the ... eosinophils) was,found in only 36% of asthmatics not ...
... Mozes HealthDay Reporter , THURSDAY, Jan. 5 ... double their risk of developing a particularly advanced form ... large new European study suggests. The possible link ... (AMD), a significant cause of blindness in seniors. ...
... Proton therapy, a type of external beam radiation therapy, ... according to two new studies published in the January ... (Red Journal), the American Society for Radiation Oncology,s ... study, researchers at the University of Florida in Jacksonville, ...
... Jan. 5 (HealthDay News) -- Children and young adults ... for complications from the flu and should receive flu ... in Ohio in February 2011. Of the 130 ... young adults with neurological and neurodevelopmental conditions, 76 (58 ...
... cost paid for statins (drugs to lower cholesterol) in ... insurance is approximately 400 percent higher than comparable costs ... These findings, from the Boston University School of Medicine ... results of a comprehensive comparison of prescription drug costs ...
Cached Medicine News:Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3Health News:A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 3Health News:Proton therapy effective prostate cancer treatment 2Health News:Study finds statin costs 400 percent higher in US compared to UK 2
... Swing doors, 8 shelves. Over-sized ... doors. Fluorescent interior lighting. Self-Contained System ... foot cord. Full One Year Warranty on ... Warranty on Compressor. Also available as ...
... Independent controls for Digital Thermostat and Digital ... steel. , Interiorwhite anodized aluminum with ... Oversized refrigeration (134A). , Temperature range ... self-closing doors. , Foamed-in-place polyurethane high ...
... The HC Series Large Capacity Refigerators ... embryos, semen, or biological samples at liquid-nitrogen ... holding times and capacities are available to ... Two low profile HCL models are also ...
... refrigerators from Taylor-Wharton are uniquely designed to ... box-type storage racks and the lower operating ... The RackSystems are available in four convenient ... 750 x 2ml vials to 4800 x ...
Medicine Products: